Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

Back

HFA Premium Access

Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

Session: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Topic: Hypertrophic Cardiomyopathy

Speaker: Professor I. Olivotto (Florence, IT)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Professor Iacopo Olivotto

University of Florence, Florence (Italy)

37 presentations

21 followers

6 more presentations in this session

Discussant panel

Access

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

Speaker: Professor S. Greene (Durham, US)

Access

Slides

Video

Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy

Speaker: Doctor A. Porcari (London, GB)

Access

Slides

Video

Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2

Speaker: Doctor J. Nunez Villota (Valencia, ES)

Access

Slides

Video

Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.

Speaker: Doctor A. Muslin (Watertown, US)

Access

Slides

Video

Access the full session

Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Speakers: Professor I. Olivotto, Professor S. Greene, Doctor A. Porcari, Doctor J. Nunez Villota, Doctor A. Muslin

Access

Video

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources